Skip to main content

Table 1 Baseline description of the two studies that provided data for the current analysis

From: Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs

  Kenya, 2003-2004 Tanzania, 2006
Number of participants 160* 108
Age, median (IQR) 3 (1-5) 5 (3-9)
Drugs, (n) Non-ACT: SP+AQ (127)
ACT: SP+AS (174) & AL (75)
ACT: SP+AS (54)
ACT-PQ: SP+AS+PQ (54)
Enrolment asexual microscopic parasite density, geometric mean (95% CI) 11,813 (9,690 - 14,402) 7,440 (1,000 - 24,280)
Microscopic gametocyte prevalence at enrolment, % (n/N) 25.5 (40/157) 22.6 (24/106)
Pfs 25 QT-NASBA gametocyte prevalence at enrolment, % (n/N) Non-ACT: 91.1 (41/45):
ACT: 89.3 (100/112)
ACT: 88.2 (45/51)
ACT-PQ: 92.3 (48/52)
Pfs 25 QT-NASBA gametocyte density at enrolment, geometric mean/μL (95% CI) Non-ACT: 1.22 (0.58-2.56)
ACT: 0.66 (0.42-1.03)
ACT: 20.26 (8.08-50.37)
ACT-PQ: 9.90 (4.43-22.11)
Included in current model fitting analysis Non-ACT: 36
ACT: 90
ACT: 36¥
ACT-PQ: 41¥
  1. IQR = interquartile range; SP = Sulphadoxine-pyrimethamine; AQ = amodiaquine; AS = artesunate; AL = artemether-lumefantrine; PQ: primaquine. * SP treated individuals (n = 152) or those without QT-NASBA data (n = 216) were excluded from the current analyses; 34 individuals were excluded because of treatment failure (n = 28) and/or failure to develop gametocytes during follow-up (n = 6); ¥26 individuals were excluded because of treatment failure (n = 21) and/or failure to develop gametocytes during follow-up (n = 8) and/or missing data (3).